Search Results - "Brucker, SY"

Interpretation of somatic POLE mutations in endometrial carcinoma by León‐Castillo, Alicia, Britton, Heidi, McConechy, Melissa K, McAlpine, Jessica N, Nout, Remi, Kommoss, Stefan, Brucker, Sara Y, Carlson, Joseph W, Epstein, Elisabeth, Rau, Tilman T, Bosse, Tjalling, Church, David N, Gilks, C Blake

“…Pathogenic somatic missense mutations within the DNA polymerase epsilon (POLE) exonuclease domain define the important subtype of ultramutated tumours…”
Get full text

Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas by León‐Castillo, Alicia, Gilvazquez, Ester, Nout, Remi, Smit, Vincent THBM, McAlpine, Jessica N, McConechy, Melissa, Kommoss, Stefan, Brucker, Sara Y, Carlson, Joseph W, Epstein, Elisabeth, Rau, Tilman T, Soslow, Robert A, Ganesan, Raji, Matias‐Guiu, Xavier, Oliva, Esther, Harrison, Beth T, Church, David N, Gilks, C Blake, Bosse, Tjalling

“…Endometrial carcinoma (EC) molecular classification based on four molecular subclasses identified in The Cancer Genome Atlas (TCGA) has gained relevance in…”
Get full text

Neovagina creation methods and their potential impact on subsequent uterus transplantation: a review by Kölle, A, Taran, F‐A, Rall, K, Schöller, D, Wallwiener, D, Brucker, SY

“…Congenital uterovaginal aplasia commonly occurs in Mayer–Rokitansky–Küster–Hauser syndrome. Various methods of neovagina creation exist, including nonsurgical…”
Get full text

Abstract P1-01-16: Detection of disseminated tumor cells in DCIS patients impacts local recurrence by Walter, VP, Taran, F-A, Wallwiener, M, Brucker, SY, Hartkopf, AD

“…Abstract Background Recently it was shown that tumor cell dissemination is an early event in breast cancer progression (Hosseini et al., Nature 2016). This has…”
Get full text

1570 Defining Target Scores and Bench Marks for a Minimal Invasive Surgery (Mic) Skills-Training to Add Objective Evaluation to the Certification Process of the German Gynecological Endoscopy Working Group (Age) by Hackethal, A, Solomayer, E, Ulrich, UA, Brucker, SY, Holthaus, B, Bojahr, B, Rimbach, S

“…To objectively enhance and add individual manual dexterity skills to the MIC certification of the german Gynecological Endoscopy Working group (AGE)…”
Get full text

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 by Curigliano, G, Burstein, H J, Winer, E P, Gnant, M, Dubsky, P, Loibl, S, Colleoni, M, Regan, M M, Piccart-Gebhart, M, Senn, H -J, Thürlimann, B, André, F, Baselga, J, Bergh, J, Bonnefoi, H, Brucker, S Y, Cardoso, F, Carey, L, Ciruelos, E, Cuzick, J, Denkert, C, Di Leo, A, Ejlertsen, B, Francis, P, Galimberti, V, Garber, J, Gulluoglu, B, Goodwin, P, Harbeck, N, Hayes, D F, Huang, C -S, Huober, J, Khaled, H, Jassem, J, Jiang, Z, Karlsson, P, Morrow, M, Orecchia, R, Osborne, K C, Pagani, O, Partridge, A H, Pritchard, K, Ro, J, Rutgers, E J T, Sedlmayer, F, Semiglazov, V, Shao, Z, Smith, I, Toi, M, Tutt, A, Viale, G, Watanabe, T, Whelan, T J, Xu, B

Get full text

Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study by Nabieva, N., Fehm, T., Häberle, L., de Waal, J., Rezai, M., Baier, B., Baake, G., Kolberg, H.-C., Guggenberger, M., Warm, M., Harbeck, N., Wuerstlein, R., Deuker, J.-U., Dall, P., Richter, B., Wachsmann, G., Brucker, C., Siebers, J.W., Popovic, M., Kuhn, T., Wolf, C., Vollert, H.-W., Breitbach, G.-P., Janni, W., Landthaler, R., Kohls, A., Rezek, D., Noesselt, T., Fischer, G., Henschen, S., Praetz, T., Heyl, V., Kühn, T., Krauss, T., Thomssen, C., Hohn, A., Tesch, H., Mundhenke, C., Hein, A., Hack, C.C., Schmidt, K., Belleville, E., Brucker, S.Y., Kümmel, S., Beckmann, M.W., Wallwiener, D., Hadji, P., Fasching, P.A.

“…Endocrine treatment (ET) with an aromatase inhibitor (AI) is the treatment of choice in post-menopausal patients with hormone receptor–positive early breast…”
Get full text

Vaginal prevalence of human papillomavirus infections in women with uterovaginal aplasia before and after laparoscopically assisted creation of a neovagina: a prospective epidemiological observational study by Rall, KK, Schoenfisch, B, Schoeller, D, Stefanescu, D, Koelle, A, Henes, M, Huebner, M, Taran, FA, Seeger, H, Iftner, A, Iftner, T, Brucker, SY

“…Objective To study vaginal as opposed to cervical human papillomavirus (HPV) acquisition with regard to true prevalence, HPV types, and the role of co‐factors…”
Get full text

Abstract P3-01-14: A nomogram to predict the likelihood of axillary non-sentinel lymph node metastases in sentinel lymph node positive primary breast cancer patients by Hartkopf, AD, Brucker, SY, Helms, G, Henzel, M, Hahn, M, Wallwiener, M, Schoenfisch, B, Taran, F-A, Fehm, TN

“…Abstract Background: Completion of axillary lymph node dissection (ALND) was long lasting standard in patients with non-metastatic primary breast cancer (PBC)…”
Get full text

Abstract OT1-11-02: PRAEGNANT - Real world evidence, translational research, big and smart data: A prospective academic translational research network for the optimization of the oncological health care quality in the adjuvant and advanced/ metastatic setting (NCT02338167) by Müller, V, Huober, J, Volz, B, Overkamp, F, Kolberg, H-C, Hadji, P, Haeberle, L, Ettl, J, Hartkopf, AD, Lux, MP, Lüftner, DI, Wallwiener, M, Taran, F-A, Beckmann, MW, Belleville, E, Wimberger, P, Hielscher, C, Geberth, M, Lermann, J, Abenhardt, A, Kurbacher, C, Wuerstlein, R, Thomssen, C, Untch, M, Janni, W, Fehm, TN, Brucker, SY, Wallwiener, D, Schneeweiss, A, Fasching, PA, Tesch, H

“…Abstract Background During the last decades the treatment of advanced breast cancer (ABC) patients has improved due to a variety of new treatment strategies…”
Get full text

Abstract P6-17-22: Progression free survival (PFS) and overall survival (OS) of patients treated with trastuzumab emtansine (T-DM1) after previous treatment with pertuzumab in patients with advanced breast cancer (NCT02338167) by Schneeweiss, A, Lux, MP, Hartkopf, AD, Volz, B, Kolberg, H-C, Hadji, P, Tesch, H, Haeberle, L, Ettl, J, Lüftner, DI, Wallwiener, M, Müller, V, Beckmann, MW, Belleville, E, Wimberger, P, Hielscher, C, Geberth, M, Lermann, J, Abenhardt, W, Kurbacher, C, Wuerstlein, R, Thomssen, C, Untch, M, Overkamp, F, Huober, J, Taran, F-A, Janni, W, Wallwiener, D, Brucker, SY, Fasching, PA, Fehm, TN

“…Abstract Background Studies leading to the approval of trastuzumab emtansine (T-DM1) have been conducted without pertuzumab as previous therapy. Therefore data…”
Get full text

Abstract P6-17-37: Therapy landscape of patients with metastatic, HER2 positive breast cancer - Data from the real world breast cancer registry PRAEGNANT (NCT02338167) by Lux, MP, Hartkopf, AD, Huober, J, Volz, B, Taran, F-A, Overkamp, F, Hadji, P, Tesch, H, Haeberle, L, Ettl, J, Lueftner, DI, Wallwiener, M, Müller, V, Beckmann, MW, Belleville, E, Wimberger, P, Hielscher, C, Geberth, M, Lermann, J, Abenhardt, W, Kurbacher, C, Wuerstlein, R, Thomssen, C, Untch, M, Fasching, PA, Janni, W, Fehm, TN, Wallwiener, D, Brucker, SY, Schneeweiss, A, Kolberg, H-C

“…Abstract Purpose: This analysis describes comprehensive real-world data concerning the use of anti-HER2 therapies in HER2 positive metastatic breast cancer…”
Get full text

Abstract P3-11-05: Reliability and acceptance of e-based survey instruments for measuring patient reported outcomes (PRO) in breast cancer patients: First results of the ePROCOM study by Wallwiener, M, Simoes, E, Hartkopf, AD, Taran, F-A, Keilmann, L, Sickenberger, N, Stevanovic, S, Belleville, E, Ladra, C, Schneeweiss, A, Wallwiener, D, Brucker, SY, Graf, J

“…Abstract Introduction Especially in oncology patients, Patient Reported Outcomes (PRO) play an increasingly important role to measure subjectively perceived…”
Get full text

Abstract GS1-06: Extended adjuvant bisphosphonate treatment over five years in early breast cancer does not improve disease-free and overall survival compared to two years of treatment: Phase III data from the SUCCESS A study by Janni, W, Friedl, TWP, Fehm, T, Müller, V, Lichtenegger, W, Blohmer, J, Lorenz, R, Forstbauer, H, Bauer, E, Fink, V, Bekes, I, Jückstock, J, Schneeweiss, A, Tesch, H, Mahner, S, Brucker, SY, Heinrich, G, Beckmann, MW, Coleman, R, Rack, B

“…Abstract Background: A recent meta-analysis has reported benefits of adjuvant bisphosphonate treatment in early breast cancer patients with improved breast…”
Get full text

Abstract P6-11-10: Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry by Wallwiener, M, Nabieva, N, Haeberle, L, Taran, FA, Hartkopf, AD, Volz, B, Overkamp, F, Brandl, AL, Kolberg, H-C, Hadji, P, Tesch, H, Ettl, J, Lux, MP, Lueftner, D, Belleville, E, Fasching, PA, Janni, W, Beckmann, MW, Wimberger, P, Hielscher, C, Fehm, T, Brucker, SY, Wallwiener, D, Schneeweiss, A, Mueller, V

“…Abstract Background: Improved progression-free survival is considered as treatment goal for patients with metastatic breast cancer (MBC) since it is assumed to…”
Get full text

Abstract GS5-07: International pooled analysis of the prognostic impact of disseminated tumor cells from the bone marrow in early breast cancer: Results from the PADDY study by Hartkopf, AD, Brucker, SY, Taran, F-A, Harbeck, N, von Au, A, Naume, B, Pierga, J-Y, Hoffmann, O, Beckmann, MW, Rydén, L, Fehm, T, Aft, R, Montserrat, S, Walter, V, Rack, B, Schuetz, F, Borgen, E, Ta, M-H, Bittner, A-K, Fasching, P, Fernö, M, Krawczyk, N, Weilbaecher, K, Margelí, M, Hahn, M, Jueckstock, J, Domschke, C, Bidard, F-C, Kasimir-Bauer, S, Schoenfisch, B, Kurt, AG, Wallwiener, M, Gebauer, G, Wallwiener, D, Janni, W, Pantel, K

“…Abstract Introduction As early breast cancer might relapse even after complete removal of breast and lymphnodes, the disease must persist in secondary sites…”
Get full text

Reproductive Outcomes in Subjects Following Radiofrequency Volumetric Thermal Ablation (RFVTA) of Their Symptomatic Myomas: A Retrospective Case Series by Berman, JM, Thiel, J, Brucker, SY

Get full text

Abstract PD1-02: Cancer predisposition genes in metastatic breast cancer – Association with metastatic pattern, prognosis, patient and tumor characteristics by Fasching, PA, Hu, C, Hart, SN, Polley, EC, Lee, KY, Gnanolivu, RD, Lilyquist, J, Hartkopf, AD, Taran, FA, Janni, W, Hadji, P, Tesch, H, Haeberle, L, Ettl, J, Lux, MP, Lueftner, D, Wallwiener, M, Mueller, V, Beckmann, MW, Belleville, E, Wimberger, P, Untch, M, Kolberg, H-C, Fehm, TN, Overkamp, F, Wallwiener, D, Brucker, SY, Schneeweiss, A, Couch, F

“…Abstract Background New treatment strategies for metastatic breast cancer (mBC) are mainly driven by therapies against specific targets. BRCA mutations are one…”
Get full text

Abstract P3-11-07: Factors associated with first line chemotherapy use in patients with hormone receptor positive, HER2 negative metastatic breast cancer – data from the PRAEGNANT breast cancer registry by Huober, J, Fasching, PA, Taran, F-A, Volz, B, Overkamp, F, Kolberg, HC, Hadji, P, Tesch, H, Haeberle, L, Ettl, J, Hartkopf, AD, Lux, MP, Lueftner, D, Wallwiener, M, Mueller, V, Beckmann, MW, Belleville, E, Wimberger, P, Hielscher, C, Geberth, M, Fersis, N, Abenhardt, W, Kurbacher, C, Wuerstlein, R, Thomssen, C, Untch, M, Janni, W, Wallwiener, D, Brucker, SY, Schneeweiss, A, Fehm, TN

“…Abstract Background For breast cancer patients with metastases which are not life threatening national and international guidelines recommend the exhaustion of…”
Get full text

Abstract P5-21-09: Overall survival of metastatic breast cancer patients – data from the PRAEGNANT breast cancer registry by Taran, F-A, Fasching, PA, Volz, B, Huober, J, Overkamp, F, Kolberg, HC, Hadji, P, Tesch, H, Haeberle, L, Ettl, J, Lux, MP, Hartkopf, AD, Lueftner, D, Wallwiener, M, Müller, V, Beckmann, MW, Belleville, E, Wimberger, P, Hielscher, C, Geberth, M, Fersis, N, Abenhardt, W, Kurbacher, C, Wuerstlein, R, Thomssen, C, Untch, M, Janni, W, Fehm, TN, Wallwiener, D, Brucker, SY, Schneeweiss, A

“…Abstract Background Breast Cancer registries can help to understand how patient groups are treated outside clinical trials and what outcome is to expected for…”
Get full text